Biocon’s subsidiary company -- Biocon Biologics has raised Rs 1125 crore through Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) and allotted 1,125 OCDs having face value of Rs 1 crore each. The board of directors at its meeting held on December 09, 2020 has approved and allotted the same.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.